Patents by Inventor Christian Wiesmann

Christian Wiesmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE
    Publication number: 20110105464
    Abstract: Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: October 29, 2010
    Publication date: May 5, 2011
    Inventors: Georgette Castanedo, Richard Goldsmith, Janet Gunzner, Tim Heffron, Kimberly Malesky, Simon Mathieu, Alan Olivero, Daniel P. Sutherlin, Vickie Tsui, Shumei Wang, Christian Wiesmann, Bing-Yan Zhu, Jennafer Dotson, Adrian Folkes, Stephen Shuttleworth, Sally Oxenford, Tim Hancox, Tracy Bayliss
  • Crystal structure of CRIg and C3b:CRIg complex
    Patent number: 7930109
    Abstract: The present invention concerns determination of the crystal structure of the macrophage specific receptor, CRIg (earlier referred to as STIgMA), and its complex with the C3b and C3c subunits of complement C3 (C3b:CRIg and C3c:CRIg complexes). The invention further concerns the use of the crystal structure of CRIg or the C3b:CRIg complex to screen for and identify molecules structurally and/or functionally related to CRIg, including CRIg agonists and antagonists.
    Type: Grant
    Filed: December 14, 2009
    Date of Patent: April 19, 2011
    Assignee: Genentech, Inc.
    Inventors: Philip Hass, Jianping Yin, Kenneth Katschke, Micah Steffek, Menno Van Lookeren Campagne, Christian Wiesmann
  • ANTI-VEGF ANTIBODIES
    Publication number: 20110020346
    Abstract: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.
    Type: Application
    Filed: July 27, 2010
    Publication date: January 27, 2011
    Applicant: Genentech, Inc.
    Inventors: Germaine Fuh, Hans-Peter Gerber, Wei-Ching Liang, Frederic A. Fellouse, Sachdev S. Sidhu, Christian Wiesmann
  • ANTI-VEGF ANTIBODIES
    Publication number: 20110014198
    Abstract: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.
    Type: Application
    Filed: June 15, 2010
    Publication date: January 20, 2011
    Applicant: Genentech, Inc.
    Inventors: Germaine Fuh, Hans-Peter Gerber, Wei-Ching Liang, Frederic A. Fellouse, Sachdev S. Sidhu, Christian Wiesmann
  • CRYSTAL STRUCTURE OF THE COMPLEX OF HEPATOCYTE GROWTH FACTOR BETA CHAIN WITH MET RECEPTOR AND METHODS OF USE
    Publication number: 20110012894
    Abstract: The disclosure provides a crystal structure of a complex of the HGF ?-chain with am extracellular fragment of the Met receptor, as well as use of the crystal structure in the design, identification, and selection of ligands that modulate the Met Receptor and the interaction of HGF with the Met receptor.
    Type: Application
    Filed: May 20, 2010
    Publication date: January 20, 2011
    Applicant: Genentech, Inc.
    Inventors: Christian Wiesmann, Jennifer Stamos
  • Phosphoinositide 3-kinase inhibitor compounds and methods of use
    Patent number: 7846929
    Abstract: Compounds of Formulas Ia and Ib, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: April 24, 2007
    Date of Patent: December 7, 2010
    Assignees: Genentech, Inc., Piramed Limited
    Inventors: Adrian Folkes, Stephen Shuttleworth, Sally Oxenford, Tim Hancox, Tracy Bayliss, Georgette Castanedo, Richard Goldsmith, Janet Gunzner, Tim Heffron, Kimberly Malesky, Simon Mathieu, Alan Olivero, Daniel P. Sutherlin, Vickie Tsui, Shumei Wang, Christian Wiesmann, Bing-Yan Zhu, Jennafer Dotson
  • Crystal structures and methods using same
    Publication number: 20100291114
    Abstract: The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention concerns modulators of FGFR3 function, and the identification and uses of said modulators.
    Type: Application
    Filed: March 24, 2010
    Publication date: November 18, 2010
    Applicant: Genentech, Inc.
    Inventor: Christian Wiesmann
  • Crystal Structure of CRIg and C3B:CRIg Complex
    Publication number: 20100291694
    Abstract: The present invention concerns determination of the crystal structure of the macrophage specific receptor, CRIg (earlier referred to as STIgMA), and its complex with the C3b and C3c subunits of complement C3 (C3b:CRIg and C3c:CRIg complexes). The invention further concerns the use of the crystal structure of CRIg or the C3b:CRIg complex to screen for and identify molecules structurally and/or functionally related to CRIg, including CRIg agonists and antagonists.
    Type: Application
    Filed: December 14, 2009
    Publication date: November 18, 2010
    Inventors: Philip Hass, Jianping Yin, Kenneth Katschke, Micah Steffek, Menno Van Lookeren Campagne, Christian Wiesmann
  • Anti-VEGF antibodies
    Patent number: 7811785
    Abstract: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.
    Type: Grant
    Filed: January 27, 2006
    Date of Patent: October 12, 2010
    Assignee: Genentech, Inc.
    Inventors: Germaine Fuh, Hans-Peter Gerber, Wei-Ching Liang, Frederic A. Fellouse, Sachdev S. Sidhu, Christian Wiesmann
  • ANTI-FGFR3 ANTIBODIES AND METHODS USING SAME
    Publication number: 20100247531
    Abstract: The invention provides FGFR3 antibodies, and compositions comprising and methods of using these antibodies.
    Type: Application
    Filed: March 24, 2010
    Publication date: September 30, 2010
    Applicant: Genentech, Inc.
    Inventors: Avi Ashkenazi, Jing Qing, Christian Wiesmann, Yan Wu
  • HGF BETA CHAIN VARIANTS
    Publication number: 20100210826
    Abstract: The invention provides HGF/Met modulators comprising HGF having mutations in regions that affect HGF function, and antagonists that target said regions. The invention further provides methods of identifying, making and using these modulators.
    Type: Application
    Filed: April 27, 2010
    Publication date: August 19, 2010
    Applicant: Genentech, Inc.
    Inventors: Daniel K. Kirchhofer, Robert A. Lazarus, Christian Wiesmann
  • Crystal structure of CRIg and C3b:CRIg complex
    Patent number: 7776573
    Abstract: The present invention concerns determination of the crystal structure of the macrophage specific receptor, CRIg (earlier referred to as STIgMA), and its complex with the C3b and C3c subunits of complement C3 (C3b:CRIg and C3c:CRIg complexes). The invention further concerns the use of the crystal structure of CRIg or the C3b:CRIg complex to screen for and identify molecules structurally and/or functionally related to CRIg, including CRIg agonists and antagonists.
    Type: Grant
    Filed: May 30, 2007
    Date of Patent: August 17, 2010
    Assignee: Genentech, Inc.
    Inventors: Philip Hass, Jianping Yin, Kenneth Katschke, Micah Steffek, Menno Van Lookeren Campagne, Christian Wiesmann
  • ANTI-VEGF ANTIBODIES
    Publication number: 20100189719
    Abstract: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.
    Type: Application
    Filed: February 4, 2010
    Publication date: July 29, 2010
    Applicant: Genentech, Inc.
    Inventors: Germaine Fuh, Hans-Peter Gerber, Wei-Ching Liang, Frederic A. Fellouse, Sachdev S. Sidhu, Christian Wiesmann
  • Anti-VEGF antibodies
    Patent number: 7758859
    Abstract: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.
    Type: Grant
    Filed: April 27, 2006
    Date of Patent: July 20, 2010
    Assignee: Genentech, Inc.
    Inventors: Germaine Fuh, Hans-Peter Gerber, Wei-Ching Liang, Frederic A. Fellouse, Sachdev S. Sidhu, Christian Wiesmann
  • Crystal structure of the complex of hepatocyte growth factor beta chain with met receptor and methods of use
    Patent number: 7754458
    Abstract: The disclosure provides a crystal structure of a complex of the HGF ?-chain with am extracellular fragment of the Met receptor, as well as use of the crystal structure in the design, identification, and selection of ligands that modulate the Met Receptor and the interaction of HGF with the Met receptor.
    Type: Grant
    Filed: January 17, 2008
    Date of Patent: July 13, 2010
    Assignee: Genentech, Inc.
    Inventors: Christian Wiesmann, Jennifer Stamos
  • CRYSTAL STRUCTURES OF NEUROPILIN FRAGMENTS AND NEUROPILIN-ANTIBODY COMPLEXES
    Publication number: 20100150919
    Abstract: The invention provides crystal structures of neuropilin 1 (Nrp1) and neuropilin 2 (Nrp2) fragments alone and in complex with anti-neuropilin antibodies, and method for their use. The invention further provides anti-Nrp antibodies and methods for their therapeutic applications.
    Type: Application
    Filed: May 17, 2007
    Publication date: June 17, 2010
    Inventors: Brent A. Appleton, Christian Wiesmann, Yan Wu
  • Affinity matured CRIg variants
    Publication number: 20100150908
    Abstract: The present invention concerns affinity matured CRIg variants. In particular, the invention concerns CRIg variants having increased binding affinity to C3b and retaining selective binding to C3b over C3.
    Type: Application
    Filed: May 6, 2009
    Publication date: June 17, 2010
    Inventors: Sachdev S. Sidhu, Bing Li, Menno Van Lookeren Campagne, Christian Wiesmann
  • HGF beta chain variants
    Patent number: 7737115
    Abstract: The invention provides HGF/Met modulators comprising HGF having mutations in regions that affect HGF function, and antagonists that target said regions. The invention further provides methods of identifying, making and using these modulators.
    Type: Grant
    Filed: April 17, 2006
    Date of Patent: June 15, 2010
    Assignee: Genetech, Inc.
    Inventors: Daniel K. Kirchhofer, Robert A. Lazarus, Christian Wiesmann
  • Anti-VEGF antibodies
    Patent number: 7691977
    Abstract: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.
    Type: Grant
    Filed: October 19, 2006
    Date of Patent: April 6, 2010
    Assignee: Genentech, Inc.
    Inventors: Germaine Fuh, Hans-Peter Gerber, Wei-Ching Liang, Frederic A. Fellouse, Sachdev S. Sidhu, Christian Wiesmann
  • Prevention and treatment of complement-associated eye conditions
    Publication number: 20090181017
    Abstract: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.
    Type: Application
    Filed: May 22, 2008
    Publication date: July 16, 2009
    Inventors: Philip Hass, Yin Jianping, Kenneth Katschke, JR., Micah Steffek, Christian Wiesmann, Menno Van Lookeren Campagne